Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV.

Cancer Chemother Pharmacol. 2018 Jul;82(1):55-63. doi: 10.1007/s00280-018-3591-y. Epub 2018 Apr 27.

PMID:
29704010
2.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

PMID:
28807367
3.

Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?

Silverton A, Raad RA, Katz L, Downey A, Muggia FM.

Ecancermedicalscience. 2016 Jun 7;10:646. doi: 10.3332/ecancer.2016.646. eCollection 2016.

4.

Intraperitoneal Therapy for Ovarian Cancer.

Muggia FM.

J Clin Oncol. 2016 Mar 10;34(8):882. doi: 10.1200/JCO.2015.62.8370. Epub 2016 Feb 1. No abstract available.

PMID:
26834061
5.

Utility of endometrial sampling prior to risk-reducing hysterectomy in a patient with Lynch syndrome.

Frey MK, David-West G, Mittal KR, Muggia FM, Pothuri B.

Ecancermedicalscience. 2016 Jan 18;10:613. doi: 10.3332/ecancer.2016.613. eCollection 2016.

6.

Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.

Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB.

J Clin Oncol. 2015 Dec 10;33(35):4219-26. doi: 10.1200/JCO.2015.60.7481. Epub 2015 Oct 26. No abstract available.

PMID:
26503202
7.

Chronic thalidomide and chemoembolization for hepatocellular carcinoma.

Wu J, Ng J, Christos PJ, Goldenberg AS, Sparano J, Sung MW, Hochster HS, Muggia FM.

Oncologist. 2014 Dec;19(12):1229-30. doi: 10.1634/theoncologist.2014-0283. Epub 2014 Oct 31.

8.

Introduction: why a supplement on taxanes?

Muggia FM.

Anticancer Drugs. 2014 May;25(5):481. doi: 10.1097/CAD.0000000000000078. No abstract available.

PMID:
24705370
9.

The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.

Safra T, Rogowski O, Muggia FM.

Int J Gynecol Cancer. 2014 Mar;24(3):488-95. doi: 10.1097/IGC.0000000000000086.

PMID:
24457564
10.

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.

Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, Alvear M, Haviv I, Muggia FM.

Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68. doi: 10.1093/annonc/mdt315.

PMID:
24131973
11.
12.

Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact.

Wu J, Joseph SO, Muggia FM.

Oncology (Williston Park). 2012 Oct;26(10):936-43.

13.

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM.

Eur J Cancer. 2012 Oct;48(15):2361-8. doi: 10.1016/j.ejca.2012.04.001. Epub 2012 Apr 26.

PMID:
22541893
14.

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.

J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi: 10.1200/JCO.2010.33.3005. Epub 2011 May 31.

15.

Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?

Echarri Gonzalez MJ, Green R, Muggia FM.

Oncology (Williston Park). 2011 Feb;25(2):156-65, 170. Review.

16.

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM.

Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15.

17.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM.

J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.

PMID:
20516432
18.

A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.

Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, Christos PJ, Doyle LA, Millward M, Muggia FM, Pavlick AC.

PLoS One. 2010 Jan 20;5(1):e8714. doi: 10.1371/journal.pone.0008714.

19.
20.

Heidelberger symposium on the 50th anniversary of fluoropyrimidines.

Muggia FM.

Mol Cancer Ther. 2009 May;8(5):991. doi: 10.1158/1535-7163.MCT-08-0732. Epub 2009 Apr 21. No abstract available.

21.

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK.

Cancer. 2009 Apr 1;115(7):1395-403. doi: 10.1002/cncr.24152. Review.

22.

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK.

Cancer. 2009 Mar 1;115(5):1028-35. doi: 10.1002/cncr.24084.

23.

Brain metastases from choriocarcinoma: two patients illustrating key management issues.

Chen T, Ginosar D, Fink M, Chen A, Cieplinski W, Curtin J, Muggia FM.

J Chemother. 2008 Jun;20(3):405-7. No abstract available.

PMID:
18606606
24.

New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.

Muggia FM.

Semin Oncol. 2006 Dec;33(6 Suppl 12):S18-24. Review.

PMID:
17223446
25.

Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective.

Grann VR, Muggia FM.

J Natl Cancer Inst. 2006 May 3;98(9):570-1. No abstract available.

PMID:
16670377
26.

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.

J Clin Oncol. 2005 Sep 1;23(25):6107-16.

PMID:
16135477
27.

Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM.

Clin Cancer Res. 2005 Aug 15;11(16):5912-9.

28.

Phase 1 clinical trials in oncology.

Muggia FM.

N Engl J Med. 2005 Jun 9;352(23):2451-3; author reply 2451-3. No abstract available.

PMID:
15948269
29.

Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 15):19-24. Review.

PMID:
15726535
30.

Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 14):17-24. Review.

PMID:
15726530
31.

Liposomal anthracycline treatment for ovarian cancer.

Markman M, Gordon AN, McGuire WP, Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 13):91-105. Review.

PMID:
15717739
32.

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. Review.

PMID:
15717738
33.

Platinums: extending their therapeutic spectrum.

Muggia FM, Fojo T.

J Chemother. 2004 Nov;16 Suppl 4:77-82. Review.

PMID:
15688617
34.

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.

Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML.

Gynecol Oncol. 2005 Jan;96(1):108-11.

PMID:
15589588
35.

'Retarded pharmaceuticals' assuming a clinical role.

Muggia FM.

Onkologie. 2004 Oct;27(5):437-8. No abstract available.

36.

Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Muggia FM, Blessing JA, McGehee R, Monk BJ.

Gynecol Oncol. 2004 Aug;94(2):483-7.

PMID:
15297192
37.

Re: 'Radiation recall dermatitis induced by pegylated liposomal doxorubicin'.

Muggia FM.

Anticancer Drugs. 2004 Jan;15(1):35. No abstract available.

PMID:
15090741
38.

The emerging roles of screening and prevention in women's cancer.

Muggia FM.

Oncologist. 2004;9(2):228-31. No abstract available.

39.

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Feb;92(2):639-43.

PMID:
14766259
40.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM.

J Clin Oncol. 2004 Jan 1;22(1):120-6.

PMID:
14701774
41.
42.

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.

Lu MJ, Sorich J, Hazarika M, Kim M, Del Priore G, Jacobs AJ, Chiang C, Liu PC, Fusco E, Curtin JP, Muggia FM.

Hematol Oncol Clin North Am. 2003 Aug;17(4):969-75. Review.

PMID:
12959186
43.

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.

Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM.

Ann Oncol. 2003 Sep;14(9):1430-7.

PMID:
12954584
44.

Treatment of sarcomas: thinking out-of-the-box.

Muggia FM, Pavlick A.

Cancer Invest. 2003 Apr;21(2):321-2. No abstract available.

PMID:
12743996
45.

Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.

Haigentz M Jr, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, Mirchandani D, Sewak S, Pavlick A, Volm M, Hamilton A, Muggia FM.

Anticancer Drugs. 2003 Apr;14(4):321-6.

PMID:
12679737
46.

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R.

Clin Cancer Res. 2003 Mar;9(3):1145-54.

47.

Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.

Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving CR.

J Liposome Res. 2002 Feb-May;12(1-2):165-72.

PMID:
12604051
48.

A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.

Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M, Sorich J, Muggia FM.

Anticancer Drugs. 2003 Jan;14(1):67-72.

PMID:
12544260
49.

Boosting bioavailability to topotecan: what do we gain?

Muggia FM.

J Clin Oncol. 2003 Jan 1;21(1):177; author reply 177. No abstract available.

PMID:
12506192
50.

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM, Perez-Soler R.

Mol Cancer Ther. 2002 Aug;1(10):841-9.

Supplemental Content

Loading ...
Support Center